Spiramide (AMI-193) 是一种有效和选择性的5-HT2和dopamine D2受体拮抗剂,Ki值分别为 2 nM 和 3 nM。Spiramide 对 5-HT2 受体的选择性与5-HT1C受体 (Ki=4300 nM) 相比大于 2000 倍。Spiramide 具有抗精神病活性。
生物活性 | Spiramide (AMI-193) is a potent and selective antagonist of5-HT2anddopamine D2 receptor, withKis of 2 nM and 3 nM, respectively. Spiramide has >2000-fold selectivity for 5-HT2versus5-HT1C(Ki=4300 nM) receptors. Spiramide exhibits antipsychotic activity[1][2][3]. |
IC50& Target[1] | 5-HT2Receptor 2 nM (Ki) | D2Receptor 3 nM (Ki) | 5-HT1AReceptor 50 nM (Ki) | D1Receptor 2530 nM (Ki) | 5-HT1CReceptor 4300 nM (Ki) |
|
体外研究 (In Vitro) | Spiramide retains affinity for 5-HT1Asites (Ki=50 nM) and also binds at dopamine D2 sites (Ki=3 nM), but possesses low affinity for dopamine D1 sites (Ki=2530 nM)[1].
|
体内研究 (In Vivo) | AMI-193 (0.003-0.01 mg/kg; i.m.) dose-dependently decreases response rate in monkeys under a fixed-interval (FI) schedule of stimulus termination[2]. AMI-193 (0.003-0.01 mg/kg; i.m.) attenuates the discriminative-stimulus effects of cocaine in drug-discrimination experiments[2]. AMI-193 (0.003-0.01 mg/kg; i.m.) reduces response rate under a second-order schedule of i.v. self-administration of cocaine (0.1 mg/infusion)[2].
Animal Model: | Adult male squirrel monkeys (850-1300 g)[2] | Dosage: | 0.003, 0.01 mg/kg | Administration: | I.m. on Tuesday, Wednesday, and Thursday the following week | Result: | Decreased the response rate. The rate-decreasing effects were reversed by cocaine. |
|
分子量 | |
性状 | |
Formula | |
CAS 号 | |
结构分类 | - Alkaloids
- Piperidine Alkaloids
|
来源 | - Plants
- Rosaceae
- Spiraea japonica
|
运输条件 | Room temperature in continental US; may vary elsewhere. |
储存方式 | -20°C, stored under nitrogen *In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen) |
溶解性数据 | In Vitro: DMSO : 20 mg/mL(52.16 mM;Need ultrasonic) 配制储备液 1 mM | 2.6078 mL | 13.0392 mL | 26.0783 mL | 5 mM | 0.5216 mL | 2.6078 mL | 5.2157 mL | 10 mM | 0.2608 mL | 1.3039 mL | 2.6078 mL |
*请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80℃, 6 months; -20℃, 1 month (stored under nitrogen)。-80℃ 储存时,请在 6 个月内使用,-20℃ 储存时,请在 1 个月内使用。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百 分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶 1. 请依序添加每种溶剂: 10% DMSO 40%PEG300 5%Tween-80 45% saline Solubility: ≥ 2 mg/mL (5.22 mM); Clear solution
此方案可获得 ≥ 2 mg/mL (5.22 mM,饱和度未知) 的澄清溶液。 以 1 mL 工作液为例,取 100 μL 20.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。 2. 请依序添加每种溶剂: 10% DMSO 90% (20%SBE-β-CDin saline) Solubility: 2 mg/mL (5.22 mM); Suspended solution; Need ultrasonic
此方案可获得 2 mg/mL (5.22 mM) 的均匀悬浊液,悬浊液可用于口服和腹腔注射。 以 1 mL 工作液为例,取 100 μL 20.0 mg/mL 的澄清 DMSO 储备液加到 900 μL20% 的 SBE-β-CD 生理盐水水溶液中,混合均匀。 *以上所有助溶剂都可在本网站选购。
|